Spots Global Cancer Trial Database for Study of Oxaliplatin and Taxotere in Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Oxaliplatin and Taxotere in Prostate Cancer
Official Title: Study of Oxaliplatin and Taxotere in Androgen Independent Prostate Cancer
Study ID: NCT00260611
Conditions
Study Description
Brief Summary: The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
Detailed Description: This is a single institution phase II study of oxaliplatin and Taxotere in patients with androgen independent prostate cancer previously treated with up to two cytotoxic chemotherapy regimens. During this study, the efficacy and safety of this combination will be evaluated. The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety). There will be up to 35 male subjects \>= 18 years of age enrolled on this single institution study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Contact Details
Name: Leonard J Appleman, MD
Affiliation: University of Pittsburgh Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
